Results for tag: "HIV First In Class Therapies"

The HIV First in Class Therapies market is a subset of the HIV/AIDS Drugs market, which is focused on the development of new treatments for HIV/AIDS. These therapies are designed to target the virus at its earliest stages, and are typically the first of their kind to be approved by the FDA. They are often more effective than existing treatments, and can be used to treat a wider range of HIV/AIDS patients. These therapies are typically more expensive than existing treatments, and are often only available to those with private insurance. The HIV First in Class Therapies market is highly competitive, with many companies vying for a share of the market. Some of the major players in this market include Gilead Sciences, Merck, ViiV Healthcare, and GlaxoSmithKline. Show Less Read more